TY - JOUR
T1 - Soluble vascular biomarkers in rheumatoid arthritis and ankylosing spondylitis
T2 - Effects of 1-year antitumor necrosis factor-α therapy
AU - Pusztai, Anita
AU - Hamar, Attila
AU - Horvath, Agnes
AU - Gulyas, Katalin
AU - Vegh, Edit
AU - Bodnar, Nora
AU - Kerekes, Gyorgy
AU - Czokolyova, Monika
AU - Szamosi, Szilvia
AU - Bodoki, Levente
AU - Hodosi, Katalin
AU - Domjan, Andrea
AU - Nagy, Gábor
AU - Szollosi, Ibolya
AU - Lopez, Luis R.
AU - Matsuura, Eiji
AU - Prohaszka, Zoltan
AU - Szanto, Sandor
AU - Nagy, Zoltan
AU - Shoenfeld, Yehuda
AU - Szekanecz, Zoltan
AU - Szucs, Gabriella
N1 - Funding Information:
This research was supported by the European Union and the State of Hungary and co-financed by the European Social Fund in the framework of TAMOP-4.2.4.A/2-11/1-2012-0001 “National Excellence Program” (ZS); by the European Union grant GINOP-2.3.2-15-2016-00050 (ZS); and by the Pfizer Investigator Initiated Research Grants no. WS1695414 and WS1695450 (ZS).
Publisher Copyright:
Copyright © 2021. All rights reserved.
PY - 2021/6/1
Y1 - 2021/6/1
N2 - Objective. Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated with cardiovascular disease. The treatment of arthritis by tumor necrosis factor-α (TNF-α) inhibitors may decrease the serum concentrations of vascular biomarkers. We determined circulating levels of oxidized low-density lipoprotein (oxLDL)/β2 glycoprotein I (β2-GPI) complexes, antibodies to 60 kDa heat shock protein (anti-Hsp60), soluble urokinase plasminogen activator receptor (suPAR), and B-type natriuretic peptide (BNP) fragment in sera of RA and AS patients undergoing anti-TNF treatment. Methods. Fifty-three patients with RA/AS were treated with etanercept or certolizumab pegol for 1 year. Circulating oxLDL/β2-GPI complex (AtherOx), anti-Hsp60 IgG, and BNP8-29 fragment levels were assessed by ELISA. suPAR levels were determined by suPARnostic Quick Triage test. Flow-mediated vasodilation (FMD), carotid intima-media thickness (CIMT), and arterial pulse wave velocity (PWV) were determined by ultrasound. Results. One-year anti-TNF treatment significantly decreased oxLDL/β2-GPI levels, as well as suPAR levels in patients with critically high suPAR levels at baseline. In RA, BNP levels were higher in seropositive vs seronegative patients. Serum levels of these vascular biomarkers variably correlated with lipids, anticitrullinated protein antibodies, rheumatoid factor, and C-reactive protein. CIMT positively correlated with BNP, and PWV with suPAR and anti-Hsp60, whereas FMD inversely associated with anti-Hsp60. In repeated measures ANOVA analysis, disease activity supported the effects of anti-TNF treatment on 12-month changes in oxLDL/β2-GPI. CIMT supported the effects of therapy on changes in anti-Hsp60 and suPAR. Conclusion. These biomarkers may be involved in the pathogenesis of atherosclerosis underlying RA/AS. TNF inhibition variably affects the serum levels of oxLDL/β2-GPI, suPAR, and BNP.
AB - Objective. Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated with cardiovascular disease. The treatment of arthritis by tumor necrosis factor-α (TNF-α) inhibitors may decrease the serum concentrations of vascular biomarkers. We determined circulating levels of oxidized low-density lipoprotein (oxLDL)/β2 glycoprotein I (β2-GPI) complexes, antibodies to 60 kDa heat shock protein (anti-Hsp60), soluble urokinase plasminogen activator receptor (suPAR), and B-type natriuretic peptide (BNP) fragment in sera of RA and AS patients undergoing anti-TNF treatment. Methods. Fifty-three patients with RA/AS were treated with etanercept or certolizumab pegol for 1 year. Circulating oxLDL/β2-GPI complex (AtherOx), anti-Hsp60 IgG, and BNP8-29 fragment levels were assessed by ELISA. suPAR levels were determined by suPARnostic Quick Triage test. Flow-mediated vasodilation (FMD), carotid intima-media thickness (CIMT), and arterial pulse wave velocity (PWV) were determined by ultrasound. Results. One-year anti-TNF treatment significantly decreased oxLDL/β2-GPI levels, as well as suPAR levels in patients with critically high suPAR levels at baseline. In RA, BNP levels were higher in seropositive vs seronegative patients. Serum levels of these vascular biomarkers variably correlated with lipids, anticitrullinated protein antibodies, rheumatoid factor, and C-reactive protein. CIMT positively correlated with BNP, and PWV with suPAR and anti-Hsp60, whereas FMD inversely associated with anti-Hsp60. In repeated measures ANOVA analysis, disease activity supported the effects of anti-TNF treatment on 12-month changes in oxLDL/β2-GPI. CIMT supported the effects of therapy on changes in anti-Hsp60 and suPAR. Conclusion. These biomarkers may be involved in the pathogenesis of atherosclerosis underlying RA/AS. TNF inhibition variably affects the serum levels of oxLDL/β2-GPI, suPAR, and BNP.
KW - Angiogenesis
KW - Anti-TNF therapy
KW - Atherosclerosis
KW - Biomarkers
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=85107427122&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107427122&partnerID=8YFLogxK
U2 - 10.3899/jrheum.200916
DO - 10.3899/jrheum.200916
M3 - Article
C2 - 33323530
AN - SCOPUS:85107427122
SN - 0315-162X
VL - 48
SP - 821
EP - 828
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 6
ER -
